<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03902431</url>
  </required_header>
  <id_info>
    <org_study_id>U01HL142107</org_study_id>
    <nct_id>NCT03902431</nct_id>
  </id_info>
  <brief_title>Translating the ABCS Into HIV Care</brief_title>
  <acronym>ABCSinHIV</acronym>
  <official_title>Implementation Research: Translating the ABCS Into HIV Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Directors Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this project is to develop and rigorously test implementation&#xD;
      strategies to address the gap in scientific knowledge of lower use of evidence-based&#xD;
      interventions commonly referred to as the ABCS (aspirin, blood pressure control, cholesterol&#xD;
      control, and smoking cessation)which contributes to the growing CVD morbidity and mortality&#xD;
      among PLH.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our project has two major aims:&#xD;
&#xD;
      Aim 1: To assess the impact of the implementation of an evidence-based, multilevel strategy&#xD;
      to reduce cardiovascular vascular disease (CVD) among PLH.&#xD;
&#xD;
      Aim 2: To assess the process of implementation of these strategies using RE-AIM QuEST. Using&#xD;
      both quantitative and qualitative methods, we evaluate the process of implementation by&#xD;
      assessing Reach, [Effectiveness addressed in Aim 1], Adoption, Implementation and Maintenance&#xD;
      whilst integrating Qualitative Evaluation for Systematic Translation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 26, 2019</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A stratified clustered randomized stepped wedge design.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>10-year CVD risk reduction</measure>
    <time_frame>12 months</time_frame>
    <description>This will be based on the ACVSD risk calculator</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>HIV</condition>
  <condition>Cardiovascular Risk Factor</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>CVD risk prior to the patient and clinician training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CVD risk after the patient and clinician training</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>ABCS training</intervention_name>
    <description>Clinicians and patients will be given information regarding the ABCS (Aspirin, Blood Pressure control,Cholesterol control, and Smoking Cessation) and for reducing CVD risk among HIV patients.</description>
    <arm_group_label>Training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Sites:&#xD;
&#xD;
          -  Serve a cohort of at least 100 HIV patients&#xD;
&#xD;
          -  Have an Electronic Health Record (EHR)&#xD;
&#xD;
          -  Agree to collaborate on implementing feasible adaptations of intervention strategies&#xD;
&#xD;
        Patients:&#xD;
&#xD;
          -  Patient of the site with a diagnosis of HIV&#xD;
&#xD;
          -  Age 40-79 years&#xD;
&#xD;
          -  ≥5% risk for CVD as calculated using the ASCVD Risk Estimator Plus&#xD;
&#xD;
          -  Willing to participate&#xD;
&#xD;
          -  No plans to leave the site in the next 12 months&#xD;
&#xD;
          -  Proficient in either English or Spanish&#xD;
&#xD;
          -  Own a cell phone with texting capabilities&#xD;
&#xD;
        Clinicians:&#xD;
&#xD;
          -  Physicians, Physicians Assistants, or Nurse Practitioners who provide direct HIV care&#xD;
             to patients&#xD;
&#xD;
          -  Work at a participating site&#xD;
&#xD;
          -  Willing to implement the project's intervention strategies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients:&#xD;
&#xD;
          -  Currently participating in another CVD trial&#xD;
&#xD;
          -  Have experienced a prior cardiac or vascular event such as myocardial infarction (MI)&#xD;
             or cerebrovascular accident (CVA)&#xD;
&#xD;
          -  Have had a CVD procedure such as installation of a stent or angioplasty&#xD;
&#xD;
          -  Have peripheral vascular disease, intermittent claudication or peripheral arterial&#xD;
             disease&#xD;
&#xD;
          -  Are pregnant&#xD;
&#xD;
          -  Lacks capacity to consent&#xD;
&#xD;
        Clinicians:&#xD;
&#xD;
        • Planning to leave the site within the next 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Fiscella, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Tobin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Directors Network, Inc; Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kevin Fiscella, MD, MPH</last_name>
    <phone>5853244563</phone>
    <email>kevin_fiscella@urmc.rochester.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonathan Tobin, PhD</last_name>
    <phone>2123820699</phone>
    <email>jntobin@cdn.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Fiscella, MD, MPH</last_name>
      <phone>585-324-4563</phone>
      <email>kevin_fiscella@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Tobin, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amneris Luque, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 1, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <last_update_submitted>November 21, 2020</last_update_submitted>
  <last_update_submitted_qc>November 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Kevin Fiscella</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

